CD274 and non-small cell lung carcinoma: The introduction of anti-programmed death receptor-1 (anti-PD-1) antibodies, pembrolizumab and nivolumab, and the anti-programmed death-ligand 1 (anti-PD-L1) antibodies, such as atezolizumab and durvalumab, has dramatically changed the treatment landscape for non-small cell lung cancer (NSCLC).